Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Vertex Reports Third Quarter 2016 Financial Results
October 25, 2016 4:03 PM EDT-Third quarter 2016 cystic fibrosis product revenues of $410 million; $234 million for ORKAMBI® (lumacaftor/ivacaftor) and $176 million for KALYDECO® (ivacaftor)-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2016 and reviewed recent progress with its approved and investigational cystic fibrosis (CF) medicines. Vertex also reiterated its financial guidance for total 2016 ORKAMBI® and KALYDECO® revenues and expenses. Key financial results include:
    Three Months Ended September 30, 2016   2015 % Change (in millions, except per share and percentage data) ORKAMBI product revenues, net $ 234 $ 131 79 % KALYDECO product revenues, net... More